⚠ Evidence warning: Clinical trials or other evidence do not support the claims that hypermobile Ehlers-Danlos syndrome, postural orthostatic tachycardia syndrome and mast cell activation syndrome form one linked disease, that 10 to 20 percent of people with hypermobile Ehlers-Danlos syndrome carry all three, that a set treatment order works, and that low-dose naltrexone modulates mast cells. This page keeps it as a report of what people, websites or other media say.
Postural Orthostatic Tachycardia Syndrome (POTS), Mast Cell Activation Syndrome (MCAS), and the Ehlers-Danlos Syndrome (EDS) Triad
Table of Contents
- What the Triad Is
- The Numbers: How Often These Conditions Cluster
- Why They Cluster: The Connective-Tissue Hypothesis
- Beyond the Triad: The Pentad
- What Postural Orthostatic Tachycardia Syndrome Looks Like in an hEDS Body
- What Mast Cell Activation Syndrome Looks Like in an hEDS Body
- The Workup Order Practitioners Describe
- What to Test — and Where
- Treatment Ordering — Joint Stabilization Before Medication
- Medications Used in the Triad
- The “Floppy Valve” Rule-Out
- Eosinophilic Gastrointestinal Disorders in the Triad
- The Tethered Cord Debate
- Self-Advocacy — The One-Page Summary
- The Psychological Weight
- When You Still Hear “It’s All in Your Head”
- Key Research Papers
- Connections
- Featured Videos
What the Triad Is
The “Ehlers-Danlos syndrome (EDS) triad” is a pattern, not a formal diagnosis. For decades, rheumatologists, cardiologists, and allergists noticed that a striking share of their hypermobile Ehlers-Danlos (hEDS) and hypermobility-spectrum-disorder (HSD) patients also had Postural Orthostatic Tachycardia Syndrome (POTS) and Mast Cell Activation Syndrome (MCAS). Put differently: a bendy person who faints when they stand up and breaks out in hives after a steak dinner is not a coincidence. It is, statistically, a type.
The three conditions are now recognized as a comorbidity cluster that behaves almost like a single multi-system disease. You can have one of the three. You can have two. And a meaningful minority have all three, often diagnosed years apart after being bounced between specialists who each saw their corner of the problem.
If you are reading this because a doctor finally said the word “triad” and you felt a decade of scattered symptoms snap into focus — you are not alone. That experience is the rule.
The Numbers: How Often These Conditions Cluster
The estimates vary by cohort and how strictly each condition is defined, but the signal is consistent:
- Postural orthostatic tachycardia syndrome in hEDS: roughly 30–50% of hEDS/HSD patients meet criteria for postural orthostatic tachycardia syndrome on active standing or tilt-table testing. In one Italian study of 102 adults with hEDS/HSD, 48% had postural orthostatic tachycardia syndrome on testing. Among dedicated postural orthostatic tachycardia syndrome clinics, up to 18–31% of postural orthostatic tachycardia syndrome patients carry an hEDS/HSD diagnosis: 18% was 7 of 39 patients in a US record review, and 31% was 28 of 91 people measured against the 2017 hEDS criteria, with a further 24% hypermobile without meeting those criteria.
- Mast cell activation syndrome in hEDS: depending on criteria, 30–70% of hEDS patients report symptoms consistent with mast cell activation; biochemical confirmation rates are described as lower but still substantial (this figure is not stated in the abstracts of the reviews by Seneviratne et al., 2017, and Afrin et al., 2021). In a US review of 195 medical records, mast cell activation syndrome was coded in 31% of patients with both postural orthostatic tachycardia syndrome and Ehlers-Danlos syndrome, compared with 2% of those without.
- All three together: in large hEDS cohorts, somewhere between 10% and 20% carry the full triad diagnostically; many more meet symptomatic criteria for all three without every lab confirmation.
These numbers are not small-study noise. They appear in dedicated hypermobility clinics across the US, UK, Spain, and Italy. Whatever is going on, it is not rare, and it is not random.
Why They Cluster: The Connective-Tissue Hypothesis
Nobody has the final answer, but four mechanisms show up in the literature repeatedly, and they probably all contribute.
1. Over-compliant vessels. Your blood vessels are lined with connective tissue. In hEDS, that tissue is measurably stretchier. When you stand up, more blood pools in the veins of your legs and abdomen than it should. Less blood returns to the heart. Your heart rate races to compensate. That is textbook postural orthostatic tachycardia syndrome — but driven by a structural, connective-tissue cause rather than a primary autonomic one.
2. Mast cells live in connective tissue. Mast cells are immune cells that release histamine, tryptase, prostaglandins, and dozens of other mediators. They are densest in the skin, gut lining, airways, and perivascular spaces — every tissue that is also rich in collagen. One proposed theory is that the same connective-tissue milieu that misbehaves in hEDS may destabilize the mast cells that live inside it, lowering their activation threshold. A 2018 review by Bonamichi-Santos and colleagues describes people with these syndromes who have symptoms compatible with mast cell disorders, and says larger studies are required to define the real correlation.
3. Shared genetic susceptibility. Hypermobile Ehlers-Danlos syndrome does not have a confirmed gene yet, but family clustering is obvious — and postural orthostatic tachycardia syndrome and mast cell activation syndrome run in the same families. Whatever gene (or set of genes) underlies hEDS very likely overlaps with the autonomic and mast-cell pathways.
4. Autonomic dysfunction feeds back. A dysregulated autonomic nervous system can directly trigger mast cell degranulation (through substance P, corticotropin-releasing hormone (CRH), and other neuropeptides). Mast cell mediators in turn affect vascular tone and heart rate. The triad is not three parallel problems — it is a loop, and kicking any one leg of it makes the others worse.
Beyond the Triad: The Pentad
Some clinicians (notably at The Ehlers-Danlos syndrome Society’s research collaborations) now describe a pentad — the triad plus two additional categories:
- Craniocervical & spinal issues — Chiari I malformation, craniocervical instability, and tethered cord syndrome, all of which appear at higher rates in hEDS.
- Eosinophilic gastrointestinal (GI) disorders — eosinophilic esophagitis (EoE), eosinophilic gastritis, and eosinophilic enteritis, which often co-occur with mast cell activation syndrome-type symptoms.
The pentad is a useful clinical shorthand, though not everyone accepts it as a formal unit. If you have hEDS plus postural orthostatic tachycardia syndrome plus mast cell activation syndrome plus swallowing problems plus a history of Chiari-like headaches, knowing the pentad exists can save you years of fragmented workup.
What Postural Orthostatic Tachycardia Syndrome Looks Like in an hEDS Body
Classic postural orthostatic tachycardia syndrome is a sustained heart-rate rise of ≥30 bpm within 10 minutes of standing (≥40 bpm in adolescents) without a drop in blood pressure. In an hEDS patient, the story usually includes:
- Feeling faint, dizzy, or “gray-out” on standing, especially in the morning or after meals.
- Heart pounding in the chest or neck when upright; calmer when lying down.
- Brain fog that is worse when vertical and clears when horizontal.
- Exercise intolerance — a flight of stairs leaves you wiped out for the rest of the day.
- Visible blood pooling in the legs (purple-red mottling, especially after showers).
- Worsening around menstruation, in heat, and after viral illnesses.
The hEDS version of postural orthostatic tachycardia syndrome often includes a prominent venous pooling picture — visibly dusky legs, compression garments feel transformative, and fluid loading helps more than it does in other postural orthostatic tachycardia syndrome subtypes. See the postural orthostatic tachycardia syndrome overview and the postural orthostatic tachycardia syndrome/mast cell activation syndrome/Ehlers-Danlos syndrome triad deep dive from the postural orthostatic tachycardia syndrome side for the full subtype discussion.
What Mast Cell Activation Syndrome Looks Like in an hEDS Body
Mast cell activation syndrome is harder to pin down because mast cells release so many different mediators and every patient’s pattern is slightly different. Common features:
- Skin: flushing (especially face, chest, ears), hives, dermatographism (pressure-drawn lines on the skin that stay red for minutes), itching without rash.
- Gastrointestinal: abdominal pain, bloating, sudden diarrhea, nausea, reflux, food reactions that are not classical immunoglobulin E (IgE) allergy (negative skin-prick tests, positive real-life reactions).
- Cardiovascular: racing heart, blood-pressure lability, presyncope — which blurs directly into the postural orthostatic tachycardia syndrome picture.
- Respiratory: wheeze, throat tightness, nasal congestion that shifts hour to hour.
- Neurological: headaches, brain fog, tingling, anxiety episodes that feel physiological rather than situational.
- Triggers: heat, alcohol, foods that low-histamine lists name such as fermented or aged foods, exercise, stress, hormonal shifts, certain medications (opiates, nonsteroidal anti-inflammatory drugs (NSAIDs), contrast dye).
The mast cell activation syndrome story in hEDS is usually “I react to everything, but never the same thing twice.” Standard allergy testing is negative. Patients get written off as anxious or “sensitive.” For a deep dive on what mast cells actually release and which organ each mediator hits, see the mast cell activation syndrome mediators and symptom map.
The Workup Order Practitioners Describe
Practitioners who treat the triad say the most common mistake is doing the three workups in the wrong order. The order they describe:
- Establishing hEDS or HSD first. This uses the 2017 International Criteria (Beighton score, systemic features, family history, exclusion of other heritable connective tissue disorders). See the hEDS 2017 criteria article.
- Checking for structural heart disease with an echocardiogram — specifically looking at the mitral valve and aortic root. Published echocardiogram studies report that routine scanning may not be needed without symptoms or a family history (see the floppy valve section).
- Testing for orthostatic intolerance. This starts with the NASA 10-minute lean test at home (cheap, reproducible), with a formal tilt-table study as the next step.
- Evaluating mast cell activation syndrome last, because it is the hardest to confirm biochemically and the most likely to be dismissed before the structural pieces are in place.
The stated reason for this order is that it stops people chasing a mast cell activation syndrome diagnosis while an undetected aortic root issue or a correctable volume-depletion problem dominates the symptoms.
What to Test — and Where
For postural orthostatic tachycardia syndrome:
- NASA 10-minute lean test. The published protocol has the person lie down undisturbed for 10 minutes, then stand leaning against a wall with only the shoulder blades touching and the heels 6–8 inches out, with heart rate and blood pressure (BP) recorded every minute for 10 minutes. A sustained rise ≥30 bpm without blood pressure drop is suggestive. Any pharmacy blood pressure cuff that shows heart rate works.
- Tilt-table test in a cardiology or autonomic clinic for formal confirmation.
- 24-hour Holter monitor to capture real-world heart rate variability.
- Basic labs: thyroid-stimulating hormone (TSH), ferritin, B12, morning cortisol, electrolytes — these look for reversible causes.
For mast cell activation syndrome:
- Serum tryptase — a baseline value, and ideally a second sample drawn 1–4 hours into a flare. A rise of 20% + 2 ng/mL during a flare is the canonical biochemical criterion.
- 24-hour urine: N-methylhistamine, prostaglandin D2 (or its metabolite 11β-PGF2α), and leukotriene E4. The collection jug is kept on ice, because these mediators degrade at room temperature.
- Chromogranin A (off proton pump inhibitors (PPIs) for 5 days beforehand).
- Genetic testing for hereditary alpha-tryptasemia (HαT) — a copy-number variant in TPSAB1 that elevates baseline tryptase. A 2016 study of 35 families and 172 further individuals linked TPSAB1 duplications with connective tissue abnormalities and dysautonomia.
For a step-by-step on which lab runs what panel and the common collection errors, see the mast cell activation syndrome testing guide.
Treatment Ordering — Joint Stabilization Before Medication
The principle practitioners put first in triad treatment is boring and non-pharmaceutical: stabilizing the joints first. Every unbraced subluxation fires pain signals, triggers autonomic stress, and in many patients triggers mast cell degranulation. Patients who jump straight to beta-blockers or H1/H2 blockers without getting their joints supported usually stall out.
The ordering practitioners describe for getting people back to functional lives:
- Ehlers-Danlos syndrome stabilization. Targeted physical therapy (isometric-first, low-load, proprioception-heavy), bracing for unstable joints, pacing education. More in the physical therapy and joint protection article.
- Postural orthostatic tachycardia syndrome volume loading. Practitioners describe 3–4 liters of fluid per day, more salt, 20–30 mmHg graduated waist-high compression, elevated head of bed, and recumbent exercise (rower, recumbent bike, swimming) ramped gradually. The 2015 Heart Rhythm Society statement says up to 2–3 liters of water and 10–12 grams of salt (sodium chloride) per day “may be considered”; that is grams of salt, not grams of sodium, and sodium is only part of salt’s weight. Extra salt raises blood pressure and fluid retention, which is a known hazard with high blood pressure, heart failure and kidney disease. In a controlled comparison of 14 patients over 6 days, a high-sodium diet (300 mEq sodium/day) raised blood volume and lowered the heart-rate jump on standing compared with a low-sodium diet, though the jump stayed well above that of healthy people (46 compared with 19 beats per minute).
- Mast cell activation syndrome foundations. Low-histamine diet trial, steering clear of obvious mediator triggers, H1 and H2 blockers daily (not as needed), and a mast cell stabilizer if needed (cromolyn, ketotifen).
- Then, and only then, escalating medications for whichever leg of the triad is still the dominant problem.
Practitioners who use this order say skipping steps does not save time and almost always wastes a year.
Medications Used in the Triad
For postural orthostatic tachycardia syndrome:
- Beta-blockers (propranolol, metoprolol, nadolol) — first-line for the tachycardia itself. Caveat: a meaningful subset of hEDS patients get worse on beta-blockers because the drugs also drop blood pressure in already-over-compliant vessels. Practitioners read feeling more faint, not less, on a beta-blocker as a sign of the wrong drug for that body rather than the wrong dose.
- Ivabradine — slows heart rate through a different mechanism (If-channel blockade) without touching blood pressure. Some practitioners describe it as the better choice in hEDS-POTS. More expensive, but increasingly covered. A randomized placebo-controlled crossover trial in 22 people with the hyperadrenergic type of postural orthostatic tachycardia syndrome found a lower heart rate (p<0.001) and better physical and social functioning, with no significant low heart rate or low blood pressure; it was not a trial in hEDS.
- Fludrocortisone — expands plasma volume; requires potassium monitoring.
- Midodrine — venoconstrictor; taken before upright activity.
- Pyridostigmine — second-line option, especially when gastrointestinal symptoms also need a prokinetic push.
For mast cell activation syndrome:
- H1 blocker daily: cetirizine, fexofenadine, or loratadine — practitioners often describe double the over-the-counter (OTC) dose. That is above the label: the OTC cetirizine and loratadine labels state no more than one tablet in 24 hours.
- H2 blocker daily: famotidine (ranitidine was removed from the market).
- Cromolyn sodium (oral, 200 mg four times daily before meals) — mast cell stabilizer, helps especially when gastrointestinal symptoms dominate.
- Ketotifen — H1 blocker plus mast cell stabilizer; compounded in the US, OTC in many countries.
- Leukotriene modifier: montelukast. Its U.S. Food and Drug Administration (FDA) boxed warning reports serious neuropsychiatric events, including agitation, aggression, depression, sleep disturbances, and suicidal thoughts and behavior.
- Low-dose naltrexone — 1.5 to 4.5 mg at bedtime. Modulates mast cells, reduces central pain sensitization, and has a solid anecdotal track record in triad patients. See the hEDS pain management article.
The “Floppy Valve” Rule-Out
Mitral valve prolapse has been reported more often in hEDS, though the echocardiogram studies differ, and hEDS has no confirmed gene or known collagen defect to explain it. In a chart review of 209 adults with classical or hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorders, 6.4% had prolapse, none severe and none needing surgery; in 568 adults at another clinic, it was 3.5% in hEDS, and those authors call cardiac defects in hEDS similar to the general population. Most mitral valve prolapse is benign, but it can cause palpitations, atypical chest pain, and presyncope that mimic postural orthostatic tachycardia syndrome exactly. Aortic root dilation, though much more characteristic of vascular Ehlers-Danlos syndrome, can also occur in hEDS in a minority of cases: 1.6% in the first study (none needing surgical repair) and 2.7% in the second.
Some practitioners describe one good transthoracic echocardiogram during the workup: if normal, another is not usually done for years unless symptoms change; if abnormal, it redirects the treatment plan. The published reports go the other way for people with no symptoms. The first study says routine echocardiograms “may not be necessary” without symptoms or a family history, and a study of 95 children and teenagers (valve abnormalities all trivial to mild, none needing intervention) says its authors do not recommend echocardiographic evaluation and surveillance without clinical findings or a positive family history.
Eosinophilic Gastrointestinal Disorders in the Triad
With triad symptoms plus trouble swallowing solid food, food impactions, persistent reflux unresponsive to proton pump inhibitors, or chronic upper-abdominal pain, the test used is an upper endoscopy with biopsies specifically counting eosinophils per high-power field. Eosinophilic esophagitis is defined as ≥15 eosinophils per high-power field. One hospital-records study found an 8-fold risk of it in people with inherited connective tissue disorders (relative risk 8.1), though only 0.8% of those patients had it. It is frequently missed because standard reflux biopsies do not count eosinophils unless explicitly requested.
EoE responds well to swallowed topical corticosteroids (budesonide slurry or fluticasone) and to a six-food elimination diet. Treating it often unwinds a large piece of what looks like mast cell activation syndrome.
The Tethered Cord Debate
A minority of hEDS patients present with lower-back pain, urinary urgency, leg weakness, and autonomic symptoms that turn out to correlate with magnetic resonance imaging (MRI) evidence of a low-lying conus medullaris or thickened filum terminale — tethered cord syndrome. A smaller number have craniocervical instability or Chiari I malformation.
Here the literature and the neurosurgical community split. Some centers perform detethering surgery with reported benefit in select patients. Other centers consider the radiographic findings over-called and the surgical outcomes inadequately studied. In one surgical series, removing the filum terminale in 78 hEDS patients without a low-lying spinal cord (and 38 typical cases) was followed by improved urinary, bowel and nerve symptoms at 3 and 12 months, and tension tests found the filum less elastic in the hEDS group; it had no sham-surgery comparison, so how much of that improvement came from the surgery itself is not known. People facing this decision commonly describe getting at least two opinions at high-volume Ehlers-Danlos syndrome centers, asking for dynamic imaging (flexion/extension magnetic resonance imaging, upright magnetic resonance imaging if available), and being wary of any center that recommends surgery at a first visit without functional testing. This is a legitimate but still-contested area of triad medicine.
Self-Advocacy — The One-Page Summary
The average triad patient spends 10 to 15 years seeing specialists before anyone connects the three conditions. Every new appointment starts from zero. The tool patient advocates describe as most useful is a one-page summary handed to every new doctor in the first 30 seconds of the visit.
What it usually holds on one page, in this order:
- Your diagnoses, in bold, with dates and the clinician who made each one.
- Beighton score, key hEDS systemic features.
- Active-stand or tilt-table results (HR rise and blood pressure pattern).
- Tryptase baseline and flare values if you have them; any positive urine mediators.
- Current medications and doses (list what has failed, not just what works).
- Allergies and medications that have caused reactions (especially opiates, nonsteroidal anti-inflammatory drug (NSAID) issues, contrast reactions).
- Your single most important question for this visit.
Patients describe handing it over with: “This is my summary. Can we start from here?” They say it changes the visit. It also protects you on days when brain fog makes it hard to explain your own history from scratch.
The Psychological Weight
Anxiety and depression are measurably elevated in triad patients, and not because the patients are weak. Living in a body whose heart rate, skin, and gut can all go sideways without warning is genuinely destabilizing. The autonomic dysregulation itself produces feelings that are physiologically indistinguishable from panic attacks. Mast cell mediators cross the blood-brain barrier and contribute to mood symptoms.
Approaches patients and clinicians describe:
- Trauma-informed therapy with a clinician who understands chronic illness — ideally one who has seen triad patients before.
- Pacing and acceptance work rather than pure cognitive-behavioral reframing. You are not catastrophizing; your body is actually doing the thing.
- Careful selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) selection. Some tricyclics and serotonin-norepinephrine reuptake inhibitors (SNRIs) help postural orthostatic tachycardia syndrome symptoms; others worsen them. Mast cell activation syndrome patients sometimes react to specific excipients in brand-name pills — compounding pharmacies help.
- Community. The sense of being “the only person like this” is corrosive, and it is false. The chronic pain article has mental-health resources that translate across the triad.
When You Still Hear “It’s All in Your Head”
Despite the growing literature, triad patients still routinely hear it. What patients describe doing:
- Not arguing in the appointment. Many say they do not win that argument, and leave with their records, their imaging, and their time intact.
- Switching clinicians. The Ehlers-Danlos syndrome Society maintains a directory of clinicians familiar with hEDS; Dysautonomia International maintains one for postural orthostatic tachycardia syndrome; The Mastocytosis Society for mast cell activation syndrome.
- Bringing objective data. A 10-minute lean test result with documented heart rate rise is harder to dismiss than a symptom narrative. A tryptase rise during a documented flare is harder still.
- Naming the literature. Patients report that “The 2017 International Classification recognizes hEDS formally, and a 2020 study found postural orthostatic tachycardia syndrome in 48% of 102 adults with hEDS or hypermobility spectrum disorder” is a sentence that shifts the room.
- The history. Every disease on this page was once considered psychiatric. The mechanisms were real; the science caught up. Your symptoms are physical, measurable, and increasingly explained.
You are not imagining this. You have a pattern with a name, a literature, and increasingly effective treatments. Finding clinicians who see it is the work; the work is worth doing.
Key Research Papers
- Kucharik AH, Chang C. The Relationship Between Hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), and Mast Cell Activation Syndrome (MCAS). Clin Rev Allergy Immunol. 2020;58(3):273–297. — PubMed PMID: 31267471 · doi:10.1007/s12016-019-08755-8
- Afrin LB, et al. Diagnosis of mast cell activation syndrome: a global “consensus-2.” Diagnosis (Berl). 2021;8(2):137–152. — PubMed PMID: 32324159 · doi:10.1515/dx-2020-0005
- Bonamichi-Santos R, Yoshimi-Kanamori K, Giavina-Bianchi P, Aun MV. Association of Postural Tachycardia Syndrome and Ehlers-Danlos Syndrome with Mast Cell Activation Disorders. Immunol Allergy Clin North Am. 2018;38(3):497–504. — PubMed PMID: 30007466
- Seneviratne SL, Maitland A, Afrin L. Mast cell disorders in Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175(1):226–236. — PubMed PMID: 28261938
- Wallman D, Weinberg J, Hohler AD. Ehlers-Danlos syndrome and postural tachycardia syndrome: a relationship study. J Neurol Sci. 2014;340(1–2):99–102. — PubMed PMID: 24685354
- Lyons JJ, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48(12):1564–1569. — PubMed PMID: 27749843
- Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12(6):e41–e63. — PubMed PMID: 25980576 · doi:10.1016/j.hrthm.2015.03.029
- Celletti C, Borsellino B, Castori M, Censi F, Calcagnini G, Camerota F, Strano S. A new insight on postural tachycardia syndrome in 102 adults with hypermobile Ehlers-Danlos Syndrome/hypermobility spectrum disorder. Monaldi Arch Chest Dis. 2020;90(2). — PubMed PMID: 32434316 · doi:10.4081/monaldi.2020.1286
- Miller AJ, Stiles LE, Sheehan T, Bascom R, Levy HP, Francomano CA, Arnold AC. Prevalence of hypermobile Ehlers-Danlos syndrome in postural orthostatic tachycardia syndrome. Auton Neurosci. 2020;224:102637. — PubMed PMID: 31954224 · doi:10.1016/j.autneu.2020.102637
- Wang E, Ganti T, Vaou E, Hohler A. The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome. Allergy Asthma Proc. 2021;42(3):243–246. — PubMed PMID: 33980338 · doi:10.2500/aap.2021.42.210022
- Taub PR, Zadourian A, Lo HC, Ormiston CK, Golshan S, Hsu JC. Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. J Am Coll Cardiol. 2021;77(7):861–871. — PubMed PMID: 33602468 · doi:10.1016/j.jacc.2020.12.029
- Garland EM, Gamboa A, Nwazue VC, et al. Effect of High Dietary Sodium Intake in Patients With Postural Tachycardia Syndrome. J Am Coll Cardiol. 2021;77(17):2174–2184. — PubMed PMID: 33926653 · doi:10.1016/j.jacc.2021.03.005
- Lee J, Vernon SD, Jeys P, Ali W, Campos A, Unutmaz D, Yellman B, Bateman L. Hemodynamics during the 10-minute NASA Lean Test: evidence of circulatory decompensation in a subset of ME/CFS patients. J Transl Med. 2020;18(1):314. — PubMed PMID: 32799889 · doi:10.1186/s12967-020-02481-y
- Asher SB, Chen R, Kallish S. Mitral valve prolapse and aortic root dilation in adults with hypermobile Ehlers-Danlos syndrome and related disorders. Am J Med Genet A. 2018;176(9):1838–1844. — PubMed PMID: 30063091 · doi:10.1002/ajmg.a.40364
- Knight DRT, Bruno KA, Singh A, et al. Cardiac defects of hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders: a retrospective cohort study. Front Cardiovasc Med. 2024;11:1332508. — PubMed PMID: 38562189 · doi:10.3389/fcvm.2024.1332508
- Paige SL, Lechich KM, Tierney ESS, Collins RT 2nd. Cardiac involvement in classical or hypermobile Ehlers-Danlos syndrome is uncommon. Genet Med. 2020;22(10):1583–1588. — PubMed PMID: 32518415 · doi:10.1038/s41436-020-0856-8
- Abonia JP, Wen T, Stucke EM, et al. High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders. J Allergy Clin Immunol. 2013;132(2):378–386. — PubMed PMID: 23608731 · doi:10.1016/j.jaci.2013.02.030
- Klinge PM, Srivastava V, McElroy A, et al. Diseased Filum Terminale as a Cause of Tethered Cord Syndrome in Ehlers-Danlos Syndrome: Histopathology, Biomechanics, Clinical Presentation, and Outcome of Filum Excision. World Neurosurg. 2022;162:e492–e502. — PubMed PMID: 35307588 · doi:10.1016/j.wneu.2022.03.038
PubMed Topic Searches
The following PubMed topic searches return current peer-reviewed work on the postural orthostatic tachycardia syndrome/mast cell activation syndrome/hEDS cluster:
- PubMed: Hypermobile EDS with POTS and MCAS
- PubMed: Ehlers-Danlos and postural orthostatic tachycardia
- PubMed: Mast cell activation syndrome and hypermobility
- PubMed: HEDS and autonomic dysfunction
- PubMed: Hereditary alpha-tryptasemia and TPSAB1 copy number
- PubMed: Eosinophilic esophagitis and connective tissue disorders
- PubMed: Tethered cord syndrome and Ehlers-Danlos
- PubMed: Ivabradine in POTS and hypermobility
- PubMed: Low-dose naltrexone and mast cell modulation
Connections
- Rheumatology
- Ehlers-Danlos Syndrome
- Hypermobile Ehlers-Danlos Syndrome and 2017 Diagnostic Criteria
- Classical and Vascular Ehlers-Danlos Syndrome
- Craniocervical Instability and AAI
- Gastrointestinal Involvement in Ehlers-Danlos Syndrome
- Pain Management in hEDS
- Pediatric Ehlers-Danlos Syndrome and Transition of Care
- Physical Therapy and Joint Protection
- Pregnancy and Ehlers-Danlos Syndrome
- Postural Orthostatic Tachycardia Syndrome
- Postural Orthostatic Tachycardia Syndrome-MCAS-EDS Triad
- Mast Cell Activation Syndrome
- Mast Cell Activation Syndrome Mediators and Symptom Map
- Mast Cell Activation Syndrome Testing Guide
- Fibromyalgia
- Chronic Pain
- Chronic Fatigue Syndrome